Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mogamulizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Moffitt Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
January 31, 2024
Lead Product(s) : Mogamulizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Moffitt Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HMO
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prebiotic Effects on Gut Microbiota, Gut Comfort and Immune Function
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
October 23, 2023
Lead Product(s) : HMO
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Citrulline
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Recipient : Texas Tech University
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of 4 Weeks of Citrulline and Glutathione Supplementation on Arterial Function
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 17, 2020
Lead Product(s) : Citrulline
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Recipient : Texas Tech University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : Loughborough University
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of L-arginine and L-citrulline Supplementation on Muscle Respiration
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 26, 2019
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Loughborough University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Citicoline Sodium
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Oregon Health and Science University
Deal Size : Inapplicable
Deal Type : Inapplicable
The Combination Effect of Citicoline and Omega-3
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
February 23, 2018
Lead Product(s) : Citicoline Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Oregon Health and Science University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Citicoline Sodium
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Biofortis Clinical Research, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Cognitive Effects of Citicoline in Men and Women With Age-Associated Memory Impairment
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
December 12, 2017
Lead Product(s) : Citicoline Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Biofortis Clinical Research, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Citicoline Sodium
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : University of Cincinnati
Deal Size : Inapplicable
Deal Type : Inapplicable
Citicoline Effects on Cortical Membrane Structure and Function
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
March 10, 2016
Lead Product(s) : Citicoline Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : University of Cincinnati
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Istradefylline
Therapeutic Area : Neurology
Study Phase : Phase III
Recipient : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 20, 2015
Lead Product(s) : Istradefylline
Therapeutic Area : Neurology
Highest Development Status : Phase III
Recipient : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Istradefylline
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Recipient : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Abuse Potential of Istradefylline
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 20, 2015
Lead Product(s) : Istradefylline
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Recipient : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Setria Glutathione
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : University of Florida
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
May 08, 2015
Lead Product(s) : Setria Glutathione
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : University of Florida
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
